XSHG
600535
Market cap3.13bUSD
Oct 09, Last price
14.20CNY
1D
1.36%
1Q
0.85%
Jan 2017
-52.08%
IPO
454.74%
Name
Tasly Pharmaceutical Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in Tianjin, China, is actively engaged in the biological medicine, health, and medical service industries within China. Its extensive product catalog encompasses a wide range of goods, including both traditional herbal and modern chemical medicines, alongside various health supplements. The firm also supplies key pharmaceutical ingredients (APIs), concentrated herbal granules, herbal extracts, and a diverse selection of tea products. Beyond its core pharmaceutical offerings, Tasly manufactures cosmetic lines featuring items such as moisturizing lotions, facial creams, eye creams, and cleansing foams. Additionally, its consumer goods division provides daily hygiene essentials like sanitary and carefree pads, in addition to specialized soaps made with honey-propolis and pollen. The company further distributes medical equipment, including different types of massage devices like tappers and cushions, as well as circulation-enhancing machines. Tasly's market presence extends globally, with significant exports directed to the United States, Russia, and numerous countries across Europe, Africa, and other parts of Asia.
Key people
Kaijing Yan
Chairman of the Board · since 2015
Jie Wei
Chief Financial Officer · since 2018
Jing Su
Director · since 2018
He Sun
Vice Chairman of the Board · since 2018
Naifeng Wu
Director
Independent Director · since 2015
Xin Liu
Independent Director · since 2018
Headquarters & legal address
天津市北辰区普济河东道2号(天士力现代中药城)
北辰区, TJ 100000
CN
北辰区, TJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||